An article published today by the Washington Post suggests pharmaceutical companies may be increasing their focus on orphan drugs and treatments for rare diseases, leaving governments to foot the bill for research on the prevention and treatment of common conditions that threaten the public health. Some US agencies are establishing partnerships with industry to bridge the gap.
